Semaglutide vs. Tirzepatide: What's the Difference?

Short answer: tirzepatide activates one more hormone receptor than semaglutide does, and across every major trial, that difference shows up as more average weight loss — with side effects that are broadly similar between the two.

If you've seen both drugs mentioned in the same breath and aren't sure what actually separates them, this breaks down the mechanism, the brand names, the trial results, and what the side effect data actually shows.

The Core Difference: One Receptor vs. Two

Semaglutide is what's called a "single-pathway" medication — it activates only the GLP-1 receptor. It mimics a natural gut hormone that increases insulin release when blood sugar is high, slows digestion, and reduces appetite.

Tirzepatide is a "dual-pathway" medication. It activates the same GLP-1 receptor, plus a second hormone receptor called GIP (glucose-dependent insulinotropic polypeptide). GIP is a separate incretin hormone released by the small intestine after eating, and on its own it also stimulates insulin release when blood sugar rises.

Activating both receptors at once produces a bigger combined effect on insulin, appetite, and energy balance than activating GLP-1 alone — which is the biological reason tirzepatide tends to outperform semaglutide on weight loss in trial after trial. It's not a different class of drug so much as a "plus one" on the same core mechanism.

Brand Names: Same Drug, Different Purpose

Both medications are sold under more than one brand name, and which brand you've heard of usually says more about what it's approved for than what's actually in it.

Semaglutide's Brand Names

• Ozempic — injectable, approved for type 2 diabetes and to reduce cardiovascular risk in adults with diabetes and existing heart disease. Typical maintenance doses run up to 2 mg weekly.
• Wegovy — injectable, approved specifically for chronic weight management at higher doses (2.4 mg weekly) — this is the dose used in the major obesity trials.
• Wegovy HD — injectable, a higher-dose version (7.2 mg weekly) approved in March 2026 for chronic weight management.
• Rybelsus — an oral tablet, approved for type 2 diabetes, taken once daily on an empty stomach.
• Wegovy (oral tablet) — a 25 mg oral tablet approved in December 2025 specifically for weight management, and launched in the US in January 2026.

Rybelsus and oral Wegovy are both oral semaglutide, but they are not the same product — Rybelsus is approved for diabetes, and oral Wegovy is approved specifically for weight management. Both are taken on an empty stomach with similar food and water timing restrictions, so if you're comparing oral semaglutide options, it matters which one you're actually being prescribed.

Tirzepatide's Two Brand Names

• Mounjaro — injectable, approved for type 2 diabetes, dosed primarily for glycemic control.
• Zepbound — injectable, approved for chronic weight management, dosed up to 15 mg weekly — the dose studied in the major obesity trials.

In both cases, the weight-loss brand (Wegovy, Zepbound) and the diabetes brand (Ozempic, Mounjaro) contain the exact same active drug — they're just labeled, dosed, and marketed for different primary uses.

What the Clinical Trials Actually Found

The Pattern Across the Data

Every source of evidence — the separate phase 3 trials, indirect statistical comparisons, the head-to-head trial, and real-world observational data — points the same direction: tirzepatide produces more average weight loss than semaglutide at the doses used for obesity treatment. A meta-analysis of comparative studies found tirzepatide patients had higher odds of reaching at least 10% weight loss than semaglutide patients.

That said, "more on average" doesn't mean "more for everyone" — individual response to either medication varies, and semaglutide still produces clinically meaningful weight loss for the large majority of people who take it.

Side Effects: More Similar Than You'd Expect

Given how different the trial results are, it's worth knowing that the side effect profiles of these two drugs are not nearly as far apart.

What They Share

Both medications carry the same class-typical gastrointestinal side effects — nausea, vomiting, diarrhea, constipation, and abdominal pain are the most common adverse events reported for each. Both also carry the same boxed warning regarding thyroid C-cell tumors found in animal studies, and both are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Where They Differ (Slightly)

If anything, some comparative research suggests tirzepatide at its higher doses (10 mg and 15 mg) may produce somewhat fewer gastrointestinal side effects than semaglutide at its approved weight-loss dose, based on indirect trial comparisons — though the practical difference for most patients is modest. Neither drug has shown a unique safety signal tied specifically to activating the second (GIP) receptor; the dominant side effects for both remain digestive.

How Dosing Typically Works

Neither medication starts at its full weight-loss dose — both are titrated upward gradually, which is a big part of why side effects tend to ease over the first several weeks of treatment rather than staying constant.

Semaglutide (Wegovy) Titration

Wegovy typically starts at a low dose and increases roughly every four weeks in a stepwise fashion, working up toward the 2.4 mg maintenance dose used in the STEP trials. The gradual increase gives the digestive system time to adjust, which is why nausea tends to be most noticeable right after a dose increase rather than throughout treatment.

Tirzepatide (Zepbound) Titration

Zepbound follows a similar stepwise approach, starting low and increasing at intervals toward the higher maintenance doses (10 mg or 15 mg) used in the SURMOUNT trials. As with semaglutide, the titration schedule is designed to balance tolerability against how quickly someone reaches an effective dose.

The exact schedule, timing, and whether someone needs to slow down or pause an increase is something a prescriber manages based on how a person is tolerating treatment — it isn't a fixed timeline that applies the same way to everyone.

Cost Considerations

Price is often the deciding factor between these two medications in practice, more so than the modest difference in side effects. List prices for both drugs run into the hundreds of dollars per month without insurance coverage, and coverage itself varies enormously depending on whether the prescription is written for the diabetes indication (Ozempic, Mounjaro) or the weight-management indication (Wegovy, Zepbound) — insurers are often far more willing to cover the former than the latter. Manufacturer savings programs, telehealth provider pricing structures, and compounded formulations (where legally available) can all significantly change what someone actually pays out of pocket, which is worth researching provider-by-provider rather than assuming list price is the real cost. For live compounded starting prices, compare injectable compounded semaglutide and injectable compounded tirzepatide.

A Third Option: Foundayo (Orforglipron)

In April 2026, the FDA approved Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1 medication for chronic weight management. Foundayo isn't semaglutide or tirzepatide — it's a different type of GLP-1 medication, a "small molecule" rather than a peptide, and unlike oral Wegovy or Rybelsus, it can be taken at any time of day without food or water restrictions.

Foundayo showed an average of 12.4% weight loss at the highest dose in clinical trials. We'll cover how it compares to semaglutide and tirzepatide options in a dedicated guide.

So Which One Is Right for You?

This isn't a question RENVA can answer for you — that's a conversation for you and a licensed prescriber, who can weigh your health history, prior response to either drug class, insurance coverage, and cost. What the data can tell you is this: tirzepatide tends to produce more weight loss on average, the two have comparable side effect profiles dominated by GI symptoms, and both require the same kind of long-term commitment to see results, since neither works as a short-term fix.

Frequently Asked Questions

For a full breakdown of how these two medications compare by brand name and approved use, see Wegovy vs. Ozempic and Wegovy vs. Zepbound.